Last reviewed · How we verify
NCT04700319
CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies
EARLY_PHASE1 trial testing CD19/CD20 CAR-T cell infusion in CAR in 30 participants. Status unknown.
1 May 2021
Quick facts
| Lead sponsor | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 30 |
| Start date | 19 April 2019 |
| Primary completion | 1 May 2021 |
| Estimated completion | 1 June 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD19/CD20 CAR-T cell infusion — full drug profile →
Conditions studied
- CAR — all drugs for CAR →
Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd. — full company profile →
Who can join
Adults 3 to 70, any sex, with CAR. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a clinical study of CD19 / CD20 CAR-T cell infusion in the treatment of relapsed or refractory hematological malignancies in CD19 / CD20 positive B cell lines. The aim of this study was to evaluate the efficacy and safety of autologous chimeric antigen receptor T cell infusion targeting CD19/CD20 in the treatment of relapsed or refractory CD19 / CD20 positive B cell line hematological malignancies.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
A close look at current γδ T-cell immunotherapy.
Ma L, Feng Y, Zhou Z. · · 2023 · cited 35× · PMID 37063836 · DOI 10.3389/fimmu.2023.1140623 -
Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
Li Y, Rezvani K, Rafei H. · · 2023 · cited 29× · PMID 37548050 · DOI 10.1111/imr.13255 -
Synthetic Biology in the Engineering of CAR-T and CAR-NK Cell Therapies: Facts and Hopes.
Clubb JD, Gao TA, Chen YY. · · 2023 · cited 24× · PMID 36454122 · DOI 10.1158/1078-0432.ccr-22-1491 -
Gamma/delta T cells as cellular vehicles for anti-tumor immunity.
Wang CQ, Lim PY, Tan AH. · · 2023 · cited 19× · PMID 38274800 · DOI 10.3389/fimmu.2023.1282758 -
Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions.
Schroeder BA, Jess J, Sankaran H, Shah NN. · · 2022 · cited 8× · PMID 35787551 · DOI 10.1097/moh.0000000000000723
Verify or expand the search:
- PubMed search for NCT04700319
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for CAR
Currently open trials in the same condition.
- NCT07283315 — Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paedia · EARLY_PHASE1 · recruiting
- NCT05043571 — CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia · Phase 1 · recruiting
- NCT05038696 — ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. · Phase 1 · recruiting
- NCT03198546 — GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression · Phase 1 · recruiting
Other PersonGen BioTherapeutics (Suzhou) Co., Ltd. trials
Trials by the same sponsor.
- NCT07338604 — Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies · EARLY_PHASE1 · recruiting
- NCT07284927 — Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies · Phase 1 · recruiting
- NCT07312630 — Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malign · EARLY_PHASE1 · recruiting
- NCT07188610 — PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma · Phase 2 · recruiting
- NCT06970951 — Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04700319 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- Last refreshed: 8 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04700319.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing